Management of salivary gland malignancies: current and developing therapies
Salivary gland tumors are rare, clinically diverse neoplasms that represent less than 1% of all malignancies. In locoregional recurrent or metastatic disease, systemic therapy is the standard approach. While numerous small phase II studies have evaluated the activity of cytotoxic agents, either alon...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-12-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/114 |
| _version_ | 1797963065769066496 |
|---|---|
| author | Mark Agulnik Camille F. McGann Bharat B. Mittal Sara C. Gordon Joel B. Epstein |
| author_facet | Mark Agulnik Camille F. McGann Bharat B. Mittal Sara C. Gordon Joel B. Epstein |
| author_sort | Mark Agulnik |
| collection | DOAJ |
| description | Salivary gland tumors are rare, clinically diverse neoplasms that represent less than 1% of all malignancies. In locoregional recurrent or metastatic disease, systemic therapy is the standard approach. While numerous small phase II studies have evaluated the activity of cytotoxic agents, either alone or in combination, the response rates are generally modest with objective response rates ranging from 15%–50%. Duration of response is cited in the range of 6–9 months. Given this, further evaluation of novel therapies is mandatory in these diseases. With the emergence of molecular targeted therapy, these tumors become optimal candidates for trials of investigational drugs and established drugs for new indications. Of note, given the often indolent nature of disease, only patients with progressive disease should be enrolled and treated on these clinical trials. Study designs must incorporate stringent inclusion criteria to enable accurate reporting of disease response and stabilization. With dedication and co-operation, patients with these rare neoplasms can be accrued to clinical trials and the establishment of new treatment guidelines will be forthcoming. |
| first_indexed | 2024-04-11T01:22:31Z |
| format | Article |
| id | doaj.art-32ecf275e98f400fab025d06dad5f528 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:22:31Z |
| publishDate | 2011-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-32ecf275e98f400fab025d06dad5f5282023-01-03T10:55:37ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652011-12-012210.4081/oncol.2008.86108Management of salivary gland malignancies: current and developing therapiesMark Agulnik0Camille F. McGann1Bharat B. Mittal2Sara C. Gordon3Joel B. Epstein4Assistant Professor of Medicine, Division of Hematology/Oncology, Northwestern University, Feinberg School of Medicine, ChicagoChief Resident, Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, ChicagoProfessor, Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, ChicagoAssociate Professor, Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, Adjunct Associate Professor, Department of Pathology, College of Medicine, University of IllinoisProfessor, Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, University of Illinois and Director, Interdisciplinary Program in Oral Cancer, Chicago Cancer Center, University of IllinoisSalivary gland tumors are rare, clinically diverse neoplasms that represent less than 1% of all malignancies. In locoregional recurrent or metastatic disease, systemic therapy is the standard approach. While numerous small phase II studies have evaluated the activity of cytotoxic agents, either alone or in combination, the response rates are generally modest with objective response rates ranging from 15%–50%. Duration of response is cited in the range of 6–9 months. Given this, further evaluation of novel therapies is mandatory in these diseases. With the emergence of molecular targeted therapy, these tumors become optimal candidates for trials of investigational drugs and established drugs for new indications. Of note, given the often indolent nature of disease, only patients with progressive disease should be enrolled and treated on these clinical trials. Study designs must incorporate stringent inclusion criteria to enable accurate reporting of disease response and stabilization. With dedication and co-operation, patients with these rare neoplasms can be accrued to clinical trials and the establishment of new treatment guidelines will be forthcoming.http://www.oncologyreviews.org/index.php/or/article/view/114Salivary gland neoplasm - Chemotherapy - Radiation therapy |
| spellingShingle | Mark Agulnik Camille F. McGann Bharat B. Mittal Sara C. Gordon Joel B. Epstein Management of salivary gland malignancies: current and developing therapies Oncology Reviews Salivary gland neoplasm - Chemotherapy - Radiation therapy |
| title | Management of salivary gland malignancies: current and developing therapies |
| title_full | Management of salivary gland malignancies: current and developing therapies |
| title_fullStr | Management of salivary gland malignancies: current and developing therapies |
| title_full_unstemmed | Management of salivary gland malignancies: current and developing therapies |
| title_short | Management of salivary gland malignancies: current and developing therapies |
| title_sort | management of salivary gland malignancies current and developing therapies |
| topic | Salivary gland neoplasm - Chemotherapy - Radiation therapy |
| url | http://www.oncologyreviews.org/index.php/or/article/view/114 |
| work_keys_str_mv | AT markagulnik managementofsalivaryglandmalignanciescurrentanddevelopingtherapies AT camillefmcgann managementofsalivaryglandmalignanciescurrentanddevelopingtherapies AT bharatbmittal managementofsalivaryglandmalignanciescurrentanddevelopingtherapies AT saracgordon managementofsalivaryglandmalignanciescurrentanddevelopingtherapies AT joelbepstein managementofsalivaryglandmalignanciescurrentanddevelopingtherapies |